Indications for: BETASERON
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Pre-medicate with analgesics and/or antipyretics on treatment days to ameliorate flu-like symptoms. May be administered by syringe and needle or Betaconnect autoinjector. Rotate inj sites. ≥18yrs: initially 0.0625mg (0.25mL) SC every other day; increase by 25% every 2 weeks to target dose of 0.25mg (1mL) SC every other day.
<18yrs: not established.
Monitor for hepatic injury; consider discontinuing if elevated transaminase levels or jaundice occurs. Depression. Suicidal ideation. Pre-existing CHF: monitor for worsening cardiac function at initiation and during treatment. Discontinue if thrombotic microangiopathy or signs/symptoms of drug-induced lupus erythematosus occurs. Myelosuppression. Monitor CBCs, differential, platelets, blood chemistries; liver function tests (at 1, 3, and 6 months then periodically). Pregnancy. Nursing mothers.
Risk of hepatic injury with concomitant hepatotoxic drugs or alcohol.
Inj site reactions (necrosis, cellulitis, abscess, inflammation, pain), lymphopenia, flu-like symptoms, myalgia, leukopenia, neutropenia, increased liver enzymes, headache, hypertonia, pain, rash, insomnia, abdominal pain, asthenia; rare: hepatic injury, anaphylaxis (discontinue if occurs), possible seizures.
Generic Drug Availability:
Single-use vials (w. prefilled diluent syringe, supplies)—5, 14